Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study.
Por:
Chunawala Z, Patel KV, Garcia KR, Segar MW, Verma S, Bayes-Genis A, Pop-Busui R, Bhatt DL, Januzzi JL Jr, Butler J, Lam CSP, Bertoni AG, Espeland M and Pandey A
Publicada:
1 mar 2026
Ahead of Print:
7 nov 2025
Resumen:
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) identifies elevated risk for developing heart failure (HF) in type 2 diabetes (T2D). Whether risk of HF subtypes associated with NT-proBNP is modifiable with an intensive lifestyle intervention (ILI) targeting weight loss is unknown. OBJECTIVES: This study aims to evaluate the association of baseline and longitudinal changes in NT-proBNP with risk of HF subtypes in T2D. In addition, we assessed whether NT-proBNP modified the association of an ILI with risk of HF subtypes. METHODS: Adults with T2D and overweight or obesity in the Look AHEAD trial were included (n = 3,959). Associations of baseline and 1-year changes in NT-proBNP with risk of HF subtypes (left ventricular ejection fraction =50% [heart failure with preserved ejection fraction (HFpEF)] and <50% (heart failure with reduced ejection fraction (HFrEF)] were evaluated in adjusted Cox models. Multiplicative interaction testing was performed to evaluate heterogeneous treatment effects of the ILI on HF subtypes across NT-proBNP concentrations. RESULTS: Elevated NT-proBNP (=125 pg/mL) at baseline and increasing NT-proBNP over 1-year follow-up (vs stable or decreasing) were each significantly associated with higher risk of both HF subtypes. The ILI was associated with lower HFpEF risk among participants with elevated but not nonelevated baseline NT-proBNP (HRs for ILI vs diabetes support and education (DSE): HR: 0.47 (95% CI: 0.24-0.90) and HR: 1.65 (95% CI: 0.93-2.91), respectively; P for interaction = 0.003). Participants with stable or decreasing, but not increasing, NT-proBNP at 1-year follow-up had lower HFpEF risk with the ILI (HRs for ILI vs DSE: HR: 0.58 (95% CI: 0.34-0.99) and HR: 1.48 (95% CI: 0.61-3.56), respectively; P for interaction = 0.01). The ILI was not significantly associated with HFrEF risk across baseline or 1-year change in NT-proBNP categories. CONCLUSIONS: In T2D, NT-proBNP can inform HF risk assessment and identify individuals who are more likely to benefit from an ILI. (Look AHEAD: Action for Health in Diabetes [Look AHEAD]; NCT00017953).
Filiaciones:
Chunawala Z:
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Patel KV:
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
Garcia KR:
Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
Segar MW:
Department of Cardiology, Texas Heart Institute, Houston, Texas, USA
Verma S:
Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
:
Heart Institute, Hospital Germans Trias i Pujol, CIBERCV, Badalona, Spain
Pop-Busui R:
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA
Bhatt DL:
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Januzzi JL Jr:
Baim Institute for Clinical Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Butler J:
Baylor Scott and White Research Institute, Dallas, Texas, USA
Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA
Lam CSP:
National Heart Centre Singapore, Duke-National University of Singapore, Singapore
Bertoni AG:
Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Espeland M:
Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Pandey A:
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
|